
Intellia Therapeutics, Alnylam seen as potential Regeneron targets, analyst says
Stocks making the biggest moves in the premarket: Boeing, Intellia Therapeutics, Perion Network & more - CNBC
1.76BUSD

See which Billionaires own this investment
Type
Common Stock
Exchange
NASDAQ
Currency Code
USD
Currency Name
US Dollar
Country Name
USA
Country ISO
US
ISIN
US45826J1051
CUSIP
45826J105
Sector
Healthcare
Industry
Biotechnology
Fiscal Year End
December
IPO date
-
Updated At
-
PE Ratio
-
PEG Ratio
-0.10
Book Value
5.16
Dividend Share
-
Dividend Yield
-
Earnings Share
-3.52
Wall Street Target Price
26.63
EPS Estimate Current Year
-3.17
EPS Estimate Next Year
-1.85
EPS Estimate Current Quarter
-0.8981
EPS Estimate Next Quarter
-0.8719
Most Recent Quarter
-
Revenue TTM
66,092,000
Gross Profit TTM
-230,670,000
EBITDA
-411,244,000
Profit Margin
0.00%
Return On Assets TTM
-30.14%
Return On Equity TTM
-56.34%
Revenue Per Share TTM
0.589
Qtly Revenue Growth YOY
-9.50%
Diluted Eps TTM
-3.52
Qtly Earnings Growth YOY
0.00%
Trailing PE
0.00
Forward PE
0
Price Sales TTM
26.32
Price Book MRQ
2.8352
Enterprise Value Revenue
22
Enterprise Value EBITDA
-5
289.84
7.21%72.60
4.81%154.89
3.58%142.12
1.26%295.50
0.74%634.62
-10.96%435.93
-3.25%808.43
-1.62%17.46
-1.30%302.44
-0.69%